Ketamine + TMS: The Future of Combined Treatment?

Ketamine and transcranial magnetic stimulation (TMS) each represent significant advances in depression treatment. Ketamine works pharmacologically, flooding the brain with neuroplastic potential through BDNF release and synaptogenesis. TMS works through neuromodulation, using magnetic pulses to directly alter activity in specific brain regions. A natural question has emerged: what happens when you combine them?

For a side-by-side comparison of ketamine and TMS as standalone treatments, see our ketamine vs TMS comparison. This post examines the emerging research on using them together.

The Theoretical Rationale

The case for combining ketamine and TMS rests on complementary mechanisms of action that could produce synergistic effects.

Ketamine's contribution: Ketamine rapidly increases BDNF and triggers the formation of new synaptic connections, primarily in the prefrontal cortex and hippocampus. This creates a period of heightened neuroplasticity during which the brain is especially receptive to forming and strengthening new neural pathways. However, ketamine's effects are somewhat diffuse; it promotes plasticity broadly rather than targeting specific circuits.

TMS's contribution: TMS delivers focused magnetic pulses to precise brain regions, most commonly the left dorsolateral prefrontal cortex (DLPFC), which is consistently underactive in depression. The magnetic pulses modulate neuronal firing patterns in the targeted area and its connected networks. TMS is precise but must work within the brain's existing capacity for change.

The combined logic: Ketamine could serve as a neuroplastic "primer," opening the brain's capacity for change, while TMS provides the directed signal that guides where that change occurs. In other words, ketamine supplies the raw materials and TMS tells the brain where to build.

What Early Research Shows

The research on ketamine-TMS combination therapy is still in its early stages, but preliminary findings are encouraging.

Case Series and Pilot Studies

Several small case series have reported on patients receiving both ketamine and TMS, either concurrently or in close temporal sequence. These reports generally describe:

• Greater magnitude of depression improvement compared to historical outcomes with either treatment alone
• Faster onset of therapeutic effects
• Some evidence of extended duration of benefit
• Acceptable safety and tolerability profiles, with no unexpected adverse events from the combination

Proposed Mechanisms of Synergy

Researchers have proposed several mechanisms by which the combination might exceed the sum of its parts:

Enhanced long-term potentiation (LTP): Ketamine's glutamatergic effects may lower the threshold for TMS-induced LTP, the cellular mechanism of learning and memory. This could mean that TMS pulses produce stronger and more durable circuit-level changes when delivered during ketamine-induced plasticity.

Network-level targeting: While ketamine broadly enhances plasticity, TMS can selectively strengthen the specific prefrontal-limbic circuits that are dysfunctional in depression. The combination could produce more targeted therapeutic effects than ketamine alone.

Temporal stacking: Administering TMS during the ketamine neuroplasticity window (24-72 hours post-dose) could allow TMS to "lock in" the synaptic changes that ketamine initiates, potentially extending the duration of benefit.

Practical Considerations

Timing Protocols

The optimal timing for combining ketamine and TMS has not been established. Current approaches include:

• Same-day administration: Ketamine in the morning, TMS in the afternoon, once acute dissociative effects have resolved
• Sequential-day administration: Ketamine on day one, TMS on days two and three during the peak neuroplasticity window
• Concurrent treatment courses: Overlapping multi-week courses of ketamine and TMS

Each approach has theoretical advantages, and comparative studies are needed to determine which timing protocol maximizes benefit.

Accessibility

One significant practical challenge is that TMS requires specialized equipment and in-person visits to a clinic, while ketamine (particularly sublingual formulations) can be administered at home. A combined protocol would likely require more in-person appointments than ketamine-only treatment, which could limit accessibility for some patients.

Cost

Both ketamine and TMS represent out-of-pocket expenses for many patients. Combining them increases the total treatment cost. However, if the combination produces substantially better or longer-lasting outcomes, the cost per unit of sustained improvement could actually be favorable.

What We Still Need to Learn

The ketamine-TMS combination remains an active area of investigation, and several critical questions are unanswered:

• Randomized controlled trials: No large RCTs have compared the combination to either treatment alone. Until such trials are completed, the evidence remains preliminary.
• Optimal patient selection: Which patients are most likely to benefit from the combination? Are there patients for whom one treatment alone is sufficient?
• Dosing and protocol optimization: What ketamine dose, TMS frequency, and timing parameters produce the best combined outcomes?
• Long-term safety: While both treatments have established safety profiles individually, the long-term safety of repeated combined use needs dedicated study.

The Bottom Line

The combination of ketamine and TMS represents one of the most intellectually compelling frontiers in depression treatment. The theoretical rationale is strong: ketamine opens the door to neuroplastic change, and TMS directs where that change occurs. Early clinical data supports the premise, but we are still in the early chapters of this research story. Larger, well-designed trials will determine whether the combination fulfills its theoretical promise.

For patients interested in ketamine therapy today, the evidence base for ketamine as a standalone treatment is robust and growing, with strong real-world outcomes data supporting its efficacy.

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.